Neogenomics Inc
NEO
ISIN null / Valor 1589606
Neogenomics Inc
UMushroom community rating:
About company
NeoGenomics Inc is a specialized laboratory and diagnostics company with a primary focus on cancer-related services. For over 18 years, it has been at the forefront of providing comprehensive testing and analysis for cancer diagnostics and clinical trials. The company operates on a global scale, employing a diverse team of professionals including physicians, scientists, and laboratory experts. These professionals collaborate closely with cancer care teams to offer critical oncological insights, aiming to significantly improve patient outcomes. NeoGenomics positions itself as a key player in the oncology sector by offering a range of services tailored to meet the needs of oncologists, pathologists, pharmaceutical companies, and academic institutions. Its offerings encompass diagnostic services, pharmaceutical services, and information services, all designed to facilitate the advancement of cancer care and treatment. Through its dedication to innovation and patient care, NeoGenomics strives to contribute to the development of new and improved cancer therapies, thereby enhancing the quality of life for those affected by cancer.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (10.10.2025):
Neogenomics Inc reported its second-quarter 2025 financial results, showcasing a 10% increase in consolidated revenue compared to the same period in 2024. The company experienced significant growth in clinical revenue and outlined updates to its full-year guidance, despite challenges in pharmaceutical revenue and a delayed product launch.
Revenue Growth
Consolidated revenue for the second quarter of 2025 reached $181 million, marking a 10% increase year-over-year. This growth was primarily driven by higher testing volumes and a 2% increase in average revenue per clinical test.
Clinical Revenue Increase
Clinical revenue surged by 16%, with a notable 23% growth in Next-Generation Sequencing (NGS). Excluding Pathline, the growth rate was 13%, highlighting the strong performance of NeoGenomics' clinical services.
Operating Expenses and Net Loss
Operating expenses rose by 32% to $125 million, mainly due to impairment charges related to asset sales and higher compensation costs. Consequently, the net loss expanded by 142% to $45 million for the quarter.
Adjusted EBITDA Stability
Adjusted EBITDA remained relatively flat, recording a positive $10.7 million compared to $10.9 million in the same quarter last year. Adjusted net loss improved slightly to $3.6 million.
Strategic Acquisition
Neogenomics completed the acquisition of Pathline, LLC for $8.0 million, aligning with its strategy to expand capabilities and presence in the Northeastern United States.
Updated Financial Guidance
The company revised its full-year 2025 revenue guidance to a 10% increase, reaffirming its position as a double-digit growth company. Neogenomics is focusing on enhancing R&D efforts, preparing for new product launches, and pursuing strategic partnerships to drive future growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1372 M
Market cap (USD)
2,234,663
Daily traded volume (Shares)
16.95 / 16.39
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
